A cancer diagnosis is daunting enough, but when the tumor is rare or mimics everyday illnesses, the path to answers can stretch for months or years. Rare cancers,those affecting fewer than about 6 in 100,000 people annually,often evade early detection…
In the world of brain tumor pathology, few molecular findings carry as much practical weight as MGMT promoter methylation. When a pathology report mentions that the MGMT gene promoter is methylated (or “silenced”), it often signals better news than the…
Brain cancer, particularly gliomas, remains one of the most challenging diagnoses a person can face, yet advances in molecular understanding have brought new hope to patients and families. Among the most significant breakthroughs is the discovery of IDH mutations in…
